Bloomberg Business

GSK and CureVac to Push Forward With Flu, Covid Vaccines

GSK Plc and CureVac NV are planning further patient trials of their messenger RNA vaccines for flu and Covid-19 after promising early results, though the partners still lag behind rivals in the race to expand use of mRNA technology.

Close Bitnami banner
Bitnami